U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07299149) titled 'Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma' on Nov. 21.
Brief Summary: This study is planned to prospectively evaluates the efficacy and safety of the zanubrutinib, obinutuzumab, and lenalidomide (ZGR) combination regimen in treatment-naive follicular lymphoma (FL) patients in a Chinese population.
Study Start Date: Dec. 25
Study Type: INTERVENTIONAL
Condition:
Follicular Lymphoma
Intervention:
DRUG: Induction Therapy: Zanubrutinib, obinutuzumab, lenalidomide
All enrolled patients received: Zanubrutinib: 160 mg twice daily, orally, on Days 1-28; Obinutuzumab:...